Publications by authors named "Daniel Bowles"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

618

Total Likes

219

Extended Reach

819,429

Social Features

92
P
Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT Antagonist Antiemetic Drugs.
Lauren E Thompson, Avisek Ghimire, Xia Wen, Christine Kim, Cathleen L Doherty, Daniel W Bowles

J Clin Pharmacol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma.
Aaron M Lee, Alice N Weaver, Phillip Acosta, Lauren Harris, Daniel W Bowles

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Rona Yaeger, Meredith A McKean, Rizwan Haq, J Thaddeus Beck, Matthew H Taylor, Daniel W Bowles

Cancer Discov· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
Jena D French, Bryan R Haugen, Francis P Worden, Daniel W Bowles, Andrew G Gianoukakis

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule-1 Biomarker.
Lauren E Thompson, Avisek Ghimire, Xia Wen, Christine Kim, Juliana Choza, Daniel W Bowles

J Pharmacol Clin Toxicol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Jaume Capdevila, Jolanta Krajewska, Jorge Hernando, Bruce Robinson, Steven I Sherman, Daniel W Bowles

Thyroid· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, Christina S Baik, Daniel Sw Tan, Daniel W Bowles

Future Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.
Andrew G Gianoukakis, Jennifer H Choe, Daniel W Bowles, Marcia S Brose, Lori J Wirth

Eur Thyroid J· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC.
Laurel B Darragh, Michael M Knitz, Junxiao Hu, Eric T Clambey, Jennifer Backus, Daniel Bowles

Nat Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W Bowles

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk stratification of patients undergoing outpatient lumbar decompression surgery.
Jose A Canseco, Brian A Karamian, Mark J Lambrechts, Tariq Z Issa, William Conaway, Daniel Bowles

Spine J· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A molecular guide to systemic therapy in salivary gland carcinoma.
Alice N Weaver, Stephanie Lakritz, Divneet Mandair, Mark B Ulanja, Daniel W Bowles

Head Neck· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
Ziad Bakouny, Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Daniel Bowles

JAMA Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC.
Laurel B Darragh, Michael M Knitz, Junxiao Hu, Eric T Clambey, Jennifer Backus, Daniel Bowles

Nat Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Alan L Ho, Nathan R Foster, Alex J Zoroufy, Jordan D Campbell, Francis Worden, Daniel W Bowles

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Marcia S Brose, Bruce G Robinson, Steven I Sherman, Barbara Jarzab, Chia-Chi Lin, Daniel W Bowles

Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC.
Laurel B Darragh, Michael M Knitz, Junxiao Hu, Eric T Clambey, Jennifer Backus, Daniel Bowles

Nat Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Marcia S Brose, Johannes W A Smit, Chia-Chi Lin, Masayuki Tori, Daniel W Bowles

Thyroid· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is a better value for your time? Anterior cervical discectomy and fusion versus cervical disc arthroplasty.
Austen David Katz, Junho Song, Daniel Bowles, Terence Ng, Eric Neufeld

J Craniovertebr Junction Spine· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Anterior Cervical Discectomy and Fusion Procedure Duration on Patient-Reported Outcome Measures.
Brian A Karamian, Paul D Minetos, Hannah A Levy, Gregory R Toci, Mark J Lambrechts, Daniel R Bowles

World Neurosurg· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, Elena Garralda, Luis Paz-Ares, Daniel W Bowles

Nat Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a Mandatory Prescription Drug Monitoring Program on Patient-initiated Phone Calls After Spine Surgery.
Brian A Karamian, Hareindra Jeyamohan, Paul D Minetos, Parth Kothari, Jose A Canseco, Daniel R Bowles

Clin Spine Surg· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of L5-S1 Degenerative Disc Disease on Outcomes of L4-L5 Fusion.
William Conaway, Brian A Karamian, Jennifer Z Mao, Parth Kothari, Jose A Canseco, Daniel R Bowles

Clin Spine Surg· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera.
Eric C Swei, Charlie M Fox, Daniel W Bowles, Mona N Rizeq, Joseph C Onyiah

ACG Case Rep J· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis